Taking functional precision medicine to the next level

In contrast to the analysis of biomarkers and genetic profiles, functional precision medicine uses the patient’s cells for direct testing of drug efficacy. Functional assays provide information in the best possible proximation of the patient’s response from a pool of multiple therapeutic options. They allow not only to determine the combination therapy with the highest probability of success, but in addition provide information of optimal drug ratio’s and potentially dosing recommendations to minimize side effects for the patient. PreComb has developed a novel technology to make efficient use of the patient’s tumor cells for drug profiling. The efficacy of tested therapies will be assayed in real-time by the most clinically relevant parameter – progression or remission of the tumor. Correlating the individual patient response to a comprehensive drug response database, the treating physician will be provided with a detailed analysis, classification and treatment proposal(s) to determine the best suitable therapies for the patient.

Profiling Report for Physician
Comprehensive drug profiling report for the treating physician.

Translational capacity

Any ex vivo testing aims to reflect the patient’s response as close as possible. Drug sensitivity is not only driven by genetical measures but rather by the whole tumor microenvironment. The better we can recapitulate the spatial configuration of a tumor the higher the predictive capacity of the test system. PreComb’s 3D3 technology employs microtumors which are produced directly after cell isolation from the patient’s tumor, reflecting the tumor cell composition as close as possible. Drug testing is done within 5-7 days after cell isolation in contrast to tumor organoids produced from tumor stem cells or PDX-models.

Efficient use of patient tumor tissue

Tumor material is precious and needed for routine clinical histo- and genotyping. Basically, there is only limited tumor sample available which can be used for additional in vitro diagnostic (IVD). To further open the IVD space towards patient-specific drug profiling, they must make efficient use of small amounts of tumor tissues. Microtumors can be produced with very small quantities of cells. Moreover, the 3D3 test technology does not destroy the tumor cells so that they can be used after the test for downstream analysis e.g. biomarkers or genetic profiles to further substantiate a therapeutic decision.

Time course of 3D Microtumors
Time course of drug testing with 3D microtumor: positive drug response.

Patient accessibility

It is important that patients gain broad access to technologies which support clinical therapy decisions. They must be accessible and affordable. The 3D3 microtumor test technology is designed to be fully automated and can be placed as a standalone testing device directly within the clinic. Patient biopsies are processed in the clinic and do not need to be sent to external service providers. The automation capability will lead to cost efficiency to make functional precision medicine affordable for every patient.

Drug response knowledge bank

The more drug and drug combinations can be tested per patient the higher the chances of finding the optimal treatment options. The 3D3 technology allows for testing multiple drugs, drug combinations and even exploratory therapies in parallel. With growing patient numbers, our drug response knowledge bank allows for an unprecedented correlation between the patient’s pathology, (genetic) disposition and the specific response to the drug portfolio. Using intelligent classification algorithms, the treating physician will be provided with the best personalized therapeutic options beyond the limited predictions of traditional profiling approaches.

Drug format compatibility

With the highly standardized setup of the drug profiling technology, PreComb is approaching all major drug modalities to be combined: small molecules, biologics and immune-modulatory agents.